Epigenomics' Q1 Revenues up 75 Percent on Lingering Roche Revenue | GenomeWeb
NEW YORK (GenomeWeb News) — Epigenomics last week said first-quarter revenue increased 75 percent as R&D spending rose 31 percent and net loss decreased 15 percent.
Total receipts for the three months ended March 31, 2007, increased to €820,000 ($1.12 million) from €470,000 ($640,000) year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.